Bayer setting aside USD 10bn for deals over the next two years
Bayer, the German-based drug maker, is planning to set aside USD 10bn for potential deals, according to a Fierce Biotech report, citing company CEO Marjin Dekkers.
Dekkers was quoted on a call with analysts saying that between 2014 and 2016 he plans to spend USD 15.5bn on research and development and during the same time period, USD 10 bn on small and mid-sized acquisitions in life sciences.
Source FiercePharma